Current AusVaxSafety surveillance data

Last updated 8 October 2018

MATERNAL PERTUSSIS VACCINE SAFETY DATA
From 1 July 2018, maternal pertussis vaccine is being funded for pregnant women under the National Immunisation Program. AusVaxSafety is monitoring the safety of maternal pertussis vaccines in the days following immunisation. The current reported event rates are consistent with existing data on the safety of maternal pertussis vaccines.

INFLUENZA VACCINE SAFETY DATA
Surveillance of 2018 influenza vaccine safety commenced from 1 April 2018.
The current reported event rates are consistent with existing data on influenza vaccines.

HPV VACCINE ACTIVE SURVEILLANCE DATA
From January 2018 a new HPV vaccine, Gardasil®9, is being funded under the National Immunisation Program. AusVaxSafety is monitoring the safety of HPV vaccine in 11-14 year olds. Injection site reactions, including pain, are known to occur following administration of HPV vaccines, and the current reported event rates are consistent with what are expected according to the existing data.

ZOSTER (SHINGLES) VACCINE SAFETY DATA
There is currently a low rate of events and medical attendance following zoster vaccine, which is consistent with the existing knowledge of the vaccine safety profile.
It is important to re-emphasise that zoster vaccine should not be given to immunocompromised individuals. For more information please refer to the Therapeutic Goods Administration (TGA) website.

PERTUSSIS (WHOOPING COUGH) VACCINE SAFETY DATA
Injection site reactions are known to occur following administration of acellular pertussis vaccines. The current reported event rates are consistent with existing data on pertussis vaccines.